🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

OncologyICD-10: C50

Find Recruiting Clinical Trials for Breast Cancer

Search HR+, HER2+, TNBC, metastatic, and early-stage breast cancer studies matched to your subtype.

🔍 Search Breast Cancer Trials →

About Breast Cancer

Breast cancer is the most common cancer diagnosed in women worldwide, with multiple distinct subtypes including hormone receptor-positive (HR+), HER2-positive, and triple-negative (TNBC). Treatment depends heavily on subtype, stage, and prior therapy and may include surgery, radiation, chemotherapy, targeted therapy, immunotherapy, and hormone therapy.

What Types of Breast Cancer Clinical Trials Exist?

Breast cancer clinical trials vary significantly by subtype. HR+ trials often test CDK4/6 inhibitors, PARP inhibitors, and endocrine therapies. HER2+ trials test trastuzumab combinations and antibody-drug conjugates. TNBC trials test checkpoint inhibitors, PARP inhibitors, and sacituzumab govitecan combinations. Subtype matching is critical.

Find Recruiting Breast Cancer Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Breast Cancer Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for breast cancer?▾
Recruiting breast cancer trials include studies across all subtypes: HR+ (CDK4/6 inhibitors, PARP inhibitors, novel endocrine agents), HER2+ (trastuzumab combinations, ADCs), TNBC (immunotherapy, PARP inhibitors), and early-stage/metastatic studies.
What is triple-negative breast cancer (TNBC) and what trials target it?▾
TNBC is breast cancer that lacks estrogen receptors, progesterone receptors, and HER2 expression. TNBC trials include immunotherapy (pembrolizumab), antibody-drug conjugates (sacituzumab govitecan), and PARP inhibitors for BRCA-mutated cases.
Does my breast cancer subtype affect trial eligibility?▾
Yes, significantly. Most breast cancer trials are subtype-specific. A trial for triple-negative breast cancer will typically exclude HR+ or HER2+ patients. Tidera uses semantic matching to surface trials compatible with your stated subtype.
Are there breast cancer trials for metastatic disease?▾
Yes. Many breast cancer trials focus specifically on metastatic (Stage IV) or locally advanced/unresectable disease. Tidera filters by disease stage when you specify it in your profile.

Related Conditions

Ovarian CancerLung CancerCervical Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.